CD19 and neoplasm: More profound studies with paired tumor samples before and after both CD19 CAR-T monotherapy and combination therapy that compare different clinical responsiveness would facilitate the identification of critical factors and pathways that underling the synergistic antitumor effect of anti–PD-1 and the mechanism of CD19 CAR-T resistance.